tegafur has been researched along with Thymoma in 4 studies
Thymoma: A neoplasm originating from thymic tissue, usually benign, and frequently encapsulated. Although it is occasionally invasive, metastases are extremely rare. It consists of any type of thymic epithelial cell as well as lymphocytes that are usually abundant. Malignant lymphomas that involve the thymus, e.g., lymphosarcoma, Hodgkin's disease (previously termed granulomatous thymoma), should not be regarded as thymoma. (From Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thymic carcinoma is a rare epithelial tumor of the thymus with a poor prognosis, and multimodal approaches are important for its treatment." | 2.94 | S-1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Study protocol of LOGIK1605/JART-1501. ( Ashizawa, K; Fukuda, M; Fukuoka, J; Funaki, S; Hara, M; Mukae, H; Nabeshima, K; Okumura, M; Sato, S; Seto, T; Sugio, K; Takenoyama, M; Tateyama, H; Yamazaki, T, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tsukita, Y | 1 |
| Inoue, A | 1 |
| Sugawara, S | 1 |
| Kuyama, S | 1 |
| Nakagawa, T | 1 |
| Harada, D | 1 |
| Tanaka, H | 1 |
| Watanabe, K | 1 |
| Mori, Y | 1 |
| Harada, T | 1 |
| Hino, T | 1 |
| Fujii, M | 1 |
| Ichinose, M | 1 |
| Fukuda, M | 1 |
| Funaki, S | 1 |
| Yamazaki, T | 1 |
| Sato, S | 1 |
| Mukae, H | 1 |
| Takenoyama, M | 2 |
| Fukuoka, J | 1 |
| Nabeshima, K | 1 |
| Tateyama, H | 1 |
| Ashizawa, K | 1 |
| Hara, M | 1 |
| Seto, T | 2 |
| Okumura, M | 1 |
| Sugio, K | 1 |
| Hirai, F | 1 |
| Inamasu, E | 1 |
| Toyokawa, G | 1 |
| Yoshida, T | 1 |
| Nosaki, K | 1 |
| Takenaka, T | 1 |
| Yamaguchi, M | 1 |
| Ichinose, Y | 1 |
| Shimizu, Y | 1 |
| Tsunezuka, Y | 1 |
| Tanaka, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| First-line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas[NCT05832827] | Phase 2 | 35 participants (Anticipated) | Interventional | 2023-09-04 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for tegafur and Thymoma
| Article | Year |
|---|---|
Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoco | 2020 |
S-1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Study protocol of LOGIK1605/JART-1501.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Clinical | 2020 |
2 other studies available for tegafur and Thymoma
| Article | Year |
|---|---|
Results of S-1-based chemotherapy for platinum (and antrathycline)-refractory advanced thymic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Male | 2014 |
[A case of unresectable advanced thymic carcinoma in an elderly woman responding to S-1 with good QOL maintained].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Drug Combinations; Female; Humans; Neo | 2008 |